Does rituximab aggravate pre-existing hypogammaglobulinaemia?

Rituximab, an anti-CD20 chimeric antibody, is the first monoclonal agent to be used in the therapy of cancer. It has been hailed as one of the most important therapeutic developments of the decade. While transient peripheral B cell depletion is common after rituximab therapy, immunoglobulin levels are generally not affected.

Double blind, randomised trial comparing single dose enoxacin and trimethoprim for treatment of bacterial cystitis.

Women with acute lower urinary tract symptoms were enrolled in a randomised, double blind study and received either a single 400 mg dose of enoxacin or a single 600 mg dose of trimethoprim. Twenty of 29 women with bacterial cystitis were cured with enoxacin and 22 of 26 with trimethoprim. Both drugs were highly effective for the treatment of Escherichia coli, but enoxacin was disappointing for the eradication of Staphylococcus saprophyticus.